ResearcherJohns Hopkins UniversityActive in the last 2 years
Junke Wang
Matched on ORCID iD 0000-0002-3733-5192; OpenAlex author ID A5100772951. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 45
2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 1 paper
Papers 7
- Perioperative management of pancreaticoduodenectomy for pancreatic ductal adenocarcinoma in a patient with moyamoya disease: a rare case report. Co-author DOI 10.3389/fonc.2026.1912208↗
- Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. First author DOI 10.1186/s13045-024-01576-z↗
- Consensus, debate, and prospective on pancreatic cancer treatments. Co-author DOI 10.1186/s13045-024-01613-x↗
- CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2023.06.037↗
- Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000000200↗
- Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model. Co-author DOI 10.1016/j.canlet.2022.215722↗
- Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy. Co-author DOI 10.1053/j.gastro.2022.06.027↗
Closest collaborators
The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Lei Zheng · 5 shared papers, 2022–2024 · strength 0.66
- Paper Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. DOI 10.1186/s13045-024-01576-z↗
- Paper Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therap… DOI 10.1097/js9.0000000000000200↗
- Paper CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic… DOI 10.1053/j.gastro.2023.06.037↗
- Keyu Li · 4 shared papers, 2022–2024 · strength 0.64
- Paper Consensus, debate, and prospective on pancreatic cancer treatments. DOI 10.1186/s13045-024-01613-x↗
- Paper Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. DOI 10.1186/s13045-024-01576-z↗
- Paper Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humaniz… DOI 10.1016/j.canlet.2022.215722↗
- Nan Niu · 4 shared papers, 2022–2024 · strength 0.53
- Paper Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. DOI 10.1186/s13045-024-01576-z↗
- Paper CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic… DOI 10.1053/j.gastro.2023.06.037↗
- Paper Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humaniz… DOI 10.1016/j.canlet.2022.215722↗
- Christopher L. Wolfgang · 3 shared papers, 2022–2024 · strength 0.50
- Paper Consensus, debate, and prospective on pancreatic cancer treatments. DOI 10.1186/s13045-024-01613-x↗
- Paper Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therap… DOI 10.1097/js9.0000000000000200↗
- Paper Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humaniz… DOI 10.1016/j.canlet.2022.215722↗
- Arsen Osipov · 3 shared papers, 2022–2024 · strength 0.40
- Paper Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. DOI 10.1186/s13045-024-01576-z↗
- Paper Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humaniz… DOI 10.1016/j.canlet.2022.215722↗
- Paper Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy. DOI 10.1053/j.gastro.2022.06.027↗
- Pan Li · 3 shared papers, 2022–2023 · strength 0.37
- Paper CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic… DOI 10.1053/j.gastro.2023.06.037↗
- Paper Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humaniz… DOI 10.1016/j.canlet.2022.215722↗
- Paper Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy. DOI 10.1053/j.gastro.2022.06.027↗
- Shuhao Bi · 1 shared paper, 2026 · strength 0.32
- Xiaojiang Ning · 1 shared paper, 2026 · strength 0.32
- Hongyu Zhuang · 1 shared paper, 2026 · strength 0.32
- Noelle R. Jurcak · 2 shared papers, 2023–2024 · strength 0.29
- Paper Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. DOI 10.1186/s13045-024-01576-z↗
- Paper CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic… DOI 10.1053/j.gastro.2023.06.037↗
- Brian T. Herbst · 2 shared papers, 2022–2024 · strength 0.28
- Paper Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. DOI 10.1186/s13045-024-01576-z↗
- Paper Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humaniz… DOI 10.1016/j.canlet.2022.215722↗
- Noah S Rozich · 2 shared papers, 2022–2024 · strength 0.28
- Paper Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. DOI 10.1186/s13045-024-01576-z↗
- Paper Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humaniz… DOI 10.1016/j.canlet.2022.215722↗
- Alex B. Blair · 2 shared papers, 2022–2024 · strength 0.27
- Paper Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. DOI 10.1186/s13045-024-01576-z↗
- Paper Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy. DOI 10.1053/j.gastro.2022.06.027↗
- Yao Xu · 2 shared papers, 2022–2023 · strength 0.25
- Paper CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic… DOI 10.1053/j.gastro.2023.06.037↗
- Paper Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humaniz… DOI 10.1016/j.canlet.2022.215722↗
- Richard Andrew Burkhart · 2 shared papers, 2022–2023 · strength 0.25
- Paper Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therap… DOI 10.1097/js9.0000000000000200↗
- Paper Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy. DOI 10.1053/j.gastro.2022.06.027↗
- Lei Zheng · 1 shared paper, 2024 · strength 0.24
- Jing He · 1 shared paper, 2024 · strength 0.24
- Amol Kumar Narang · 1 shared paper, 2024 · strength 0.24
- Mengni He · 1 shared paper, 2024 · strength 0.16
- Xu-Bao Liu · 1 shared paper, 2024 · strength 0.16
- Chunhui Yuan · 1 shared paper, 2024 · strength 0.16
- Quan Liao · 1 shared paper, 2023 · strength 0.14
- Christopher R. Shubert · 1 shared paper, 2023 · strength 0.14
- Ming Cui · 1 shared paper, 2023 · strength 0.14
- Jin Peng He · 1 shared paper, 2023 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.